

Item 7.01 Regulation FD Disclosure.

On November 15, 2018, a complaint was filed against Alexion Pharmaceuticals, Inc. by Chugai Pharmaceutical Co., Ltd. in the U.S. District Court for Delaware alleging that ALXN1210 infringes a U.S. patent held by Chugai. We believe that we have valid legal defenses against Chugai's infringement claims. Accordingly, we intend to oppose these claims and intend to proceed with our business plans for ALXN1210.

This Form 8-K contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995, including statements related to the Chugai litigation and our business plans for ALXN1210. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ materially from those forward-looking statements, including uncertainties related to our legal proceedings and other risks set forth from time to time in Alexion's filings with the SEC, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the period ended September 30, 2018. Alexion disclaims any obligation to update any of these forward-looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 16, 2018 ALEXION PHARMACEUTICALS, INC.

By: /s/ Douglas Barry_____

Name: Douglas Barry

Title: Vice President, Corporate Law